Researchers conducted a study to determine the effect of a national human papillomavirus (HPV) immunization program on the incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia among young women in England.
To answer the many questions regarding the roll out, risk and benefits, and timing of COVID-19 vaccine administration in children aged 5 to 11 years, The Clinical Advisor interviewed Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, a pediatric nurse practitioner and owner of Pediatric Nurse Practitioner House Calls.
The panel reviewed safety and efficacy data from a phase 2/3 study that included 2268 participants who received a 2-dose regimen of 10mcg administered 21 days apart.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
With children back in school and COVID-19 cases persisting, parents may be concerned and seek information about the vaccine. What should they know about the COVID-19 vaccine for children?
